Testa Advances in Drug Research

1. Auflage 2013
ISBN: 978-1-4832-8799-7
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 19, 581 Seiten, Web PDF

Reihe: Advances in Drug Research

Each volume in this distinguished series presents authoritative reviews on topics of broad interest in drug research and on novel and established therapeutic classes. Acknowledged experts contribute in areas such as drug design, clinical and molecular pharmacology, drug metabolism, and mechanisms of action. Reviewers have consistently praised Advances in Drug Research for its comprehensive and lucid summaries of up-to-date knowledge.

Autoren/Hrsg.

Testa, Bernard

Inhaltsverzeichnis

1;Front Cover;1
2;Advances in Drug Research;4
3;Copyright Page;5
4;Table of Contents;6
5;CONTRIBUTORS;10
6;PREFACE;12
7;CHAPTER 1. PHARMACOKINETIC CRITERIA FOR DRUG RESEARCH AND DEVELOPMENT;14
7.1;1 Introduction;19
7.2;2 Purpose of the Pharmacokinetic Registration File;24
7.3;3 In Vitro Methods;28
7.4;4 Animal Pharmacokinetics;33
7.5;5 Pharmacokinetics in Healthy Humans;47
7.6;6 Pharmacokinetics in Special Physiological Situations;65
7.7;7 Pharmacokinetics in Diseased Patients;81
7.8;8 Sample Collection and Storage;86
7.9;9 Sample Handling;89
7.10;10 Analytical Methods;91
7.11;11 Bioavailability Studies;100
7.12;12 Conduct of Trials, Good Clinical Practice and Good Laboratory Practice;116
7.13;13 Data Interpretation;117
7.14;14 Use of Computers for the Calculation of Basic Pharmacokinetic Parameters: Problems and Pitfalls;123
7.15;15 Planning of Pharmacokinetic Studies During Drug Development;133
7.16;16 The "Pharmacokinetic Expert Report" in the Registration File;134
7.17;17 Post-marketing Studies;136
7.18;18 Clinical Drug Concentration Monitoring During Drug Development;141
7.19;19 Conclusion;143
7.20;Bibliography;143
7.21;References;143
8;CHAPTER 2. INTERSPECIES PHARMACOKINETIC SCALING, BIOLOGICAL DESIGN AND NEOTENY;152
8.1;1 Introduction;152
8.2;2 Size and Scale: Isometry and Allometry;156
8.3;3 Size, Form and Structure;167
8.4;4 Pharmacokinetic Scaling;170
8.5;5 The Importance of Neoteny;190
8.6;6 Overview;201
8.7;References;204
9;CHAPTER 3. GENETIC POLYMORPHISMS OF DRUG METABOLISM;210
9.1;1 Introduction;211
9.2;2 The Debrisoquine/Sparteine-type Polymorphism of Drug Oxidation;214
9.3;3 The Mephenytoin-type Polymorphism of Drug Oxidation;230
9.4;4 The Polymorphism of N-Acetyltransferase;235
9.5;5 Concluding Remarks;245
9.6;Acknowledgement;246
9.7;References;246
10;CHAPTER 4. METAL COMPLEXES AS ANTITUMOUR AGENTS;256
10.1;1 The Role of Metal Complexes in Medicine. History and Current Status;256
10.2;2 Tumour-inhibiting Metal Complexes and the Discovery of Cisplatin;259
10.3;3 The Development of New Tumour-inhibiting Metal Complexes;266
10.4;4 Synthesis of Direct Derivatives of Cisplatin;275
10.5;5 The Development of Non-platinum Complexes;278
10.6;6 Drug Targeting;313
10.7;7 Perspectives;316
10.8;Acknowledgements;317
10.9;References;317
11;CHAPTER 5. DIGITALIS: ITS MODE OF ACTION, RECEPTOR, AND STRUCTURE—ACTIVITY RELATIONSHIPS;324
11.1;1 Introduction;326
11.2;2 The Clinical Use of Digitalis;330
11.3;3 The Biochemical Pharmacology of the Direct Effects of Digitalis on the Heart;339
11.4;4 The Topography of the Digitalis Receptor as Deduced from Structure– Activity Relationship Studies;396
11.5;5 The Endogenous Digitalis Factor and its Possible Role in the Pathogenesis of Essential Hypertension;446
11.6;6 The Role of the Neuronal System in the Action of Cardiac Glycosides;462
11.7;7 The Metabolism of Cardiac Glycosides;484
11.8;8 Structure–Activity Relationships: a Systematic Review;509
11.9;References;558
12;SUBJECT INDEX;576
13;CUMULATIVE INDEX OF AUTHORS;590
14;CUMULATIVE INDEX OF TITLES;592